12 week semaglutide program Update. I didn’t have any weightloss this week and that’s OK!Details about the weightloss are in my bio #semaglutide #semaglutidejourney #weightloss #minutemdpartner Fridays | GLP-1 Telehealth |
Description
Regulatory agencies increasingly recognize the value of surrogate endpoints, adaptive trial designs, and biomarker-driven patient stratification, particularly in areas of high unmet need
Predictive modeling and real-world data analytics can help anticipate side effect profiles and refine patient selection, thereby improving both safety and cost-effectiveness
Nationwide retrospective studies utilizing register data from Sweden and Denmark (20132021) and the UK CPRD (20072020) have revealed consistent findings, indicating that GLP-1 RAs are not associated with an elevated risk of suicidality relative to DPP-4 or SGLT-2 inhibitors [77,78]
Monitor for side effects and tolerability during transitions between semaglutide products
